NZ549778A - Combinations for treating HIV infection - Google Patents

Combinations for treating HIV infection

Info

Publication number
NZ549778A
NZ549778A NZ549778A NZ54977805A NZ549778A NZ 549778 A NZ549778 A NZ 549778A NZ 549778 A NZ549778 A NZ 549778A NZ 54977805 A NZ54977805 A NZ 54977805A NZ 549778 A NZ549778 A NZ 549778A
Authority
NZ
New Zealand
Prior art keywords
hiv
aids
reverse transcriptase
inhibitor
agent
Prior art date
Application number
NZ549778A
Other languages
English (en)
Inventor
Pin-Fang Lin
Beata Nowicka-Sans
Gregory Yamanaka
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34961940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ549778(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NZ549778A publication Critical patent/NZ549778A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ549778A 2004-03-24 2005-03-01 Combinations for treating HIV infection NZ549778A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55576704P 2004-03-24 2004-03-24
PCT/US2005/006277 WO2005102392A2 (en) 2004-03-24 2005-03-01 Combinations for treating hiv infection

Publications (1)

Publication Number Publication Date
NZ549778A true NZ549778A (en) 2010-09-30

Family

ID=34961940

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ549778A NZ549778A (en) 2004-03-24 2005-03-01 Combinations for treating HIV infection

Country Status (30)

Country Link
US (1) US7776863B2 (cg-RX-API-DMAC7.html)
EP (1) EP1732604B1 (cg-RX-API-DMAC7.html)
JP (1) JP4847441B2 (cg-RX-API-DMAC7.html)
KR (1) KR101158140B1 (cg-RX-API-DMAC7.html)
CN (1) CN1956720B (cg-RX-API-DMAC7.html)
AR (1) AR048333A1 (cg-RX-API-DMAC7.html)
AT (1) ATE474602T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005235116B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0509140A (cg-RX-API-DMAC7.html)
CA (1) CA2561146C (cg-RX-API-DMAC7.html)
CY (1) CY1111613T1 (cg-RX-API-DMAC7.html)
DE (1) DE602005022420D1 (cg-RX-API-DMAC7.html)
DK (1) DK1732604T3 (cg-RX-API-DMAC7.html)
ES (1) ES2347801T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20104925B (cg-RX-API-DMAC7.html)
HR (1) HRP20100434T1 (cg-RX-API-DMAC7.html)
IL (1) IL178141A (cg-RX-API-DMAC7.html)
IN (1) IN2012DN06436A (cg-RX-API-DMAC7.html)
MY (1) MY144318A (cg-RX-API-DMAC7.html)
NO (1) NO337116B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ549778A (cg-RX-API-DMAC7.html)
PE (1) PE20060148A1 (cg-RX-API-DMAC7.html)
PL (1) PL1732604T3 (cg-RX-API-DMAC7.html)
PT (1) PT1732604E (cg-RX-API-DMAC7.html)
RU (1) RU2367439C2 (cg-RX-API-DMAC7.html)
SI (1) SI1732604T1 (cg-RX-API-DMAC7.html)
TW (1) TWI347184B (cg-RX-API-DMAC7.html)
UA (1) UA88463C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005102392A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200607959B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US8318931B2 (en) 2005-10-28 2012-11-27 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonists and use thereof
EP1961744B1 (en) 2005-11-18 2013-04-17 Ono Pharmaceutical Co., Ltd. Basic group-containing compound and use thereof
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7501419B2 (en) * 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7572810B2 (en) * 2006-06-08 2009-08-11 Bristol-Myers Squibb Company Alkene piperidine derivatives as antiviral agents
US7504399B2 (en) 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
ES2462403T3 (es) 2008-06-25 2014-05-22 Bristol-Myers Squibb Company Diceto azolopiperidinas y azolopiperazinas como agentes anti-VIH
US8242124B2 (en) * 2008-06-25 2012-08-14 Bristol-Myers Squibb Company Diketopiperidine derivatives as HIV attachment inhibitors
US20110290821A1 (en) * 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration
EP2601174B1 (en) 2010-08-06 2014-11-26 Bristol-Myers Squibb Company Substituted indole and azaindole oxoacetyl piperazinamide derivatives
WO2012075235A1 (en) 2010-12-02 2012-06-07 Bristol-Myers Squibb Company Alkyl amides as hiv attachment inhibitors
RS54055B1 (sr) 2011-01-31 2015-10-30 Bristol-Myers Squibb Company POSTUPCI ZA PRIPREMU JEDINJENJA PROLEKA INHIBITORA VEZIVANJA HIV-a I INTERMEDIJERA
WO2012142080A1 (en) 2011-04-12 2012-10-18 Bristol-Myers Squibb Company Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
ES2616268T3 (es) 2011-08-29 2017-06-12 VIIV Healthcare UK (No.5) Limited Derivados condensados de diamina bicíclica como inhibidores de la unión de VIH
ES2609579T3 (es) 2011-08-29 2017-04-21 VIIV Healthcare UK (No.5) Limited Derivados espiro de diamina bicíclica como inhibidores de la unión del VIH
US9193725B2 (en) 2012-03-14 2015-11-24 Bristol-Meyers Squibb Company Cyclic hydrazine derivatives as HIV attachment inhibitors
ES2616492T3 (es) 2012-08-09 2017-06-13 VIIV Healthcare UK (No.5) Limited Derivados de piperidina amida como inhibidores de la fijación del VIH
WO2014025852A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Tricyclic alkene derivatives as hiv attachment inhibitors
PT2978763T (pt) * 2013-03-27 2018-04-16 Viiv Healthcare Uk No 5 Ltd Derivados de 2-cetoamida como inibidores da ligação do vih
EP3313412A4 (en) 2015-06-23 2019-01-16 CytoDyn Inc. INHIBITION OF CCL5 LIGAND BINDING AT CCR5 RECEPTOR AND CHANGING CCR5 / CCL5 AXIS SIGNALING IN INFUSION, CANCER, AUTOIMMUNE AND OTHER DISORDERS
WO2023172635A1 (en) * 2022-03-08 2023-09-14 Emory University Predictive model for variants associated with drug resistance and theranostic applications thereof
US12425371B2 (en) * 2022-09-16 2025-09-23 Cisco Technology, Inc. System and method for providing SCHC-based edge firewalling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE348839T1 (de) * 1998-03-02 2007-01-15 Univ North Carolina Acylierte betulin- und dihydrobetulinderivate, ihre herstellung und verwendung
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
RU2192870C1 (ru) * 2001-07-02 2002-11-20 Закрытое акционерное общество "Агрофарм ПитерСиб" Антивирусная композиция, способ получения ее активной компоненты и способ лечения вич-инфицированных больных этой композицией
WO2003049690A2 (en) * 2001-12-12 2003-06-19 Bristol-Myers Squibb Company Hiv integrase inhibitors
CN102153540A (zh) * 2001-12-21 2011-08-17 阿诺麦德股份有限公司 具有强效的与趋化因子受体结合的杂环化合物

Also Published As

Publication number Publication date
JP2007530540A (ja) 2007-11-01
EP1732604A2 (en) 2006-12-20
GEP20104925B (en) 2010-03-25
US20050215545A1 (en) 2005-09-29
DE602005022420D1 (de) 2010-09-02
DK1732604T3 (da) 2010-11-15
JP4847441B2 (ja) 2011-12-28
UA88463C2 (ru) 2009-10-26
WO2005102392A3 (en) 2006-07-20
CN1956720B (zh) 2010-12-15
HK1096540A1 (en) 2007-06-01
AU2005235116A1 (en) 2005-11-03
US7776863B2 (en) 2010-08-17
RU2006137555A (ru) 2008-04-27
IL178141A0 (en) 2006-12-31
ES2347801T3 (es) 2010-11-04
NO20064547L (no) 2006-10-06
IL178141A (en) 2010-11-30
PL1732604T3 (pl) 2010-12-31
CY1111613T1 (el) 2015-10-07
MY144318A (en) 2011-08-29
HRP20100434T1 (hr) 2010-09-30
AU2005235116B2 (en) 2011-03-31
CN1956720A (zh) 2007-05-02
RU2367439C2 (ru) 2009-09-20
PT1732604E (pt) 2010-09-24
EP1732604B1 (en) 2010-07-21
BRPI0509140A (pt) 2007-09-04
SI1732604T1 (sl) 2010-10-29
PE20060148A1 (es) 2006-03-04
CA2561146C (en) 2013-12-24
NO337116B1 (no) 2016-01-25
AR048333A1 (es) 2006-04-19
TW200538117A (en) 2005-12-01
KR20070011322A (ko) 2007-01-24
CA2561146A1 (en) 2005-11-03
ZA200607959B (en) 2008-06-25
WO2005102392A2 (en) 2005-11-03
KR101158140B1 (ko) 2012-06-19
ATE474602T1 (de) 2010-08-15
IN2012DN06436A (cg-RX-API-DMAC7.html) 2015-10-09
TWI347184B (en) 2011-08-21

Similar Documents

Publication Publication Date Title
AU2005235116B2 (en) Combinations for treating HIV infection
US20050215544A1 (en) Methods of treating HIV infection
US20050215543A1 (en) Methods of treating HIV infection
US20060058286A1 (en) Methods of treating HIV infection
EP2646439B1 (en) Alkyl amides as hiv attachment inhibitors
JP6073677B2 (ja) 縮合複素環式化合物およびそれらの使用
TWI344463B (en) Potassium salt of an hiv integrase inhibitor
US20030069266A1 (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7087610B2 (en) Benzothiazole antiviral agents
US7449476B2 (en) Tetrahydrocarboline antiviral agents
ES2582877T3 (es) Formulaciones de sulfato de atazanavir con un efecto de pH mejorado
HK1096540B (en) Methods of treating hiv infection
EP2696937B1 (en) Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
De Clercq et al. Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile: retroviruses and hepadnaviruses
MXPA06010885A (es) Combinaciones para tratamiento de infeccion de virus de inmunodeficiencia humana (vih)
Uckun et al. Therapeutic innovations against HIV
US20030181436A1 (en) Treatment for AIDS, HIV, and other related diseases and compounds for use therewith
Reviriego Cenicriviroc mesylate

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2016 BY CPA GLOBAL

Effective date: 20150129

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2017 BY CPA GLOBAL

Effective date: 20160129

ASS Change of ownership

Owner name: VIIV HEALTHCARE UK (NO.4) LIMITED, GB

Effective date: 20161124

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2018 BY THOMSON REUTERS

Effective date: 20170221

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2019 BY THOMSON REUTERS

Effective date: 20180217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2020 BY THOMSON REUTERS

Effective date: 20190216

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2021 BY THOMSON REUTERS

Effective date: 20200205

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2022 BY THOMSON REUTERS

Effective date: 20210206

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2023 BY ANAQUA SERVICES

Effective date: 20220218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2024 BY ANAQUA SERVICES

Effective date: 20230221

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2025 BY ANAQUA SERVICES

Effective date: 20240220

EXPY Patent expired